
Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
Here’s what you missed this week on Managed Healthcare Executive.
Each Sunday we feature a highlight reel of various articles posted on our website that week.
We’ll be back on Monday morning with more fresh content!






